A Machine Learning Approach for Early Diagnosis of Transthyretin Amyloid Cardiomyopathy Among Heart Failure Patients [PDF]
, 2023 Transthyretin Amyloid Cardiomyopathy (ATTR-CM) is a rare, progressive, and fatal disease. Prevalence of ATTR-CM ranges from 4 to 17 per 100000 cases where the mean survival time is less than 4 years.
Ahmed, Tanjim
core +1 more source
Annals of Medicine, 2023 Aims To estimate healthcare resource use and direct healthcare costs of Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in Sweden over 12 months across severity stages as defined by the New York Heart Association (NYHA).
Frida Hjalte +5 more
doaj +1 more source
Diagnostic algorithm in transthyretin amyloidosis with cardiomyopathy [PDF]
Българска кардиология, 2020 Transthyretin cardiac amyloidosis is a restrictive cardiomyopathy ((ATTR-CM), caused by an extracellular deposition of insoluble amyloid fibrils in the myocardium.
Mariana Gospodinova +11 more
doaj +3 more sources
Detecting early cardiomyopathy in transthyretin variant carriers:reappraising the diagnostic value of Perugini grade 1 radiotracer uptake on bone scintigraphy [PDF]
Purpose: To determine whether TTRv carriers with Perugini grade 1 cardiac radiotracer uptake on [99mTc]Tc- hydroxydiphosphonate bone scintigraphy have or develop ATTR-CM.Methods: This retrospective observational study was conducted at the Groningen ...
Berends, M. +12 more
core +1 more source
JACC. CardioOncology, 2020 Background: With increasing diagnoses and available treatment options for transthyretin amyloidosis cardiomyopathy (ATTR-CM), risk stratification of ATTR-CM patients is imperative.
Richard K. Cheng, MD, MSc +6 more
doaj +1 more source
Transthyretin amyloid cardiomyopathy: Treatment pipeline, clinical trials, and challenges
Journal of Public Health and Primary Care, 2021 Transthyretin amyloid cardiomyopathy (ATTR-CM) is potentially a fatal disease characterized by abnormal buildup of amyloid fibrils primarily in the heart causing progressive heart failure. It is categorized into two subtypes-hereditary ATTR and wild type
Sweety Sharma, Bhawna Sharma
doaj +1 more source
screening for transthyretin amyloid cardiomyopathy in everyday practice [PDF]
, 2019 Transthyretin amyloid cardiomyopathy (ATTR-CM) is a life-threatening, progressive, infiltrative disease caused by the deposition of transthyretin amyloid fibrils in the heart, and can often be overlooked as a common cause of heart failure.
Bokhari, Sabahat +9 more
core +3 more sources
A review of the criteria for non-invasive diagnosis of cardiac transthyretin amyloidosis [PDF]
, 2021 Introduction: Cardiac transthyretin (ATTR) amyloidosis is a progressive and fatal infiltrative cardiomyopathy (ATTR-CM) characterized by congestive cardiac failure, often with preserved left ventricular ejection fraction, and significant risk of ...
Fontana, M, Gillmore, JD, Rezk, T
core
Diagnosis and treatment of transthyretin amyloidosis cardiomyopathy: A position statement of the Polish Cardiac Society [PDF]
, 2023 Considering the rare incidence of transthyretin amyloidosis cardiomyopathy (ATTR-CM) in Poland, patients encounter difficulties at the stages of diagnosis and treatment. For successful diagnosis, it is vital to raise the suspicion of ATTR-CM, that is, to
Dąbrowska-Kugacka, Alicja +13 more
core +2 more sources
Diagnosis of Transthyretin Amyloid Cardiomyopathy
Cardiology and Therapy, 2020 Transthyretin amyloid cardiomyopathy (ATTR-CM) continues to be an easily overlooked, life-threatening, yet treatable cause of heart failure. Furthermore, its elusive diagnosis leads to late or misdiagnosis.
Adam S. Hafeez, Anthony A. Bavry
doaj +1 more source